High-quality ingredients sourced and manufactured under rigorous GMP/USP standards.
Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products in China. For nearly 10 years, we have been dedicated to exporting biological products, vaccines, and high-purity probiotics.
With annual sales exceeding 10,000,000 US dollars, we serve over 500 long-term clients worldwide, bridging the gap between advanced Chinese manufacturing and global demand.
Specializing in Bio-Fermentation, Co-Crystallization, and Pre-Mix customization, we ensure that every batch of Bifidobacterium meets the highest metabolic activity standards.
In the modern era of industrial agriculture, the transition from antibiotic growth promoters (AGPs) to sustainable, biological alternatives has reached a critical tipping point. Among the most potent tools in the veterinarian's arsenal is Bifidobacterium animalis, a genus of Gram-positive, non-motile, often branched anaerobic bacteria. As a primary colonizer of the intestinal tract in mammals and birds, Bifidobacterium plays a pivotal role in maintaining the homeostasis of the gut microbiota, which is directly linked to the animal's immune response, nutrient absorption efficiency, and overall growth performance.
The global animal probiotic market is projected to reach unprecedented heights by 2030, driven by the "One Health" initiative which emphasizes the interconnectedness of human, animal, and environmental health. We are seeing a shift from general probiotic supplementation to Precision Biotics—where specific strains like Bifidobacterium animalis ssp. lactis are selected for their robust resistance to gastric acid and bile salts.
Key trends include the integration of Postbiotics and Synbiotics (a combination of probiotics and prebiotics), which ensure that the beneficial bacteria not only survive the transit to the lower intestine but also have the necessary "fuel" to thrive and outcompete pathogenic strains like Salmonella and E. coli.
For multinational feed manufacturers and large-scale livestock integrators, the primary challenge in procuring wholesale Bifidobacterium is Stability. Unlike many other probiotic species, Bifidobacterium is strictly anaerobic, meaning exposure to oxygen during the manufacturing, packaging, or mixing process can lead to rapid degradation of CFU (Colony Forming Unit) counts.
Modern feed processing often involves high-temperature pelleting. Our Bifidobacterium strains undergo specialized micro-encapsulation to survive temperatures up to 85°C.
Procurement teams now demand a minimum shelf-life of 24 months with a degradation rate of less than 10%—a standard Jiangxi Serum Pharma strictly adheres to.
With the tightening of EU and FDA regulations, full traceability and non-GMO certification are no longer optional but a baseline for entry into the premium market.
China has emerged as a global powerhouse in bio-fermentation, not just due to scale, but through the implementation of Factory 4.0 principles. At our partner facilities, we utilize automated fermentation control systems that monitor pH, dissolved oxygen, and nutrient consumption in real-time, ensuring maximum metabolic activity of the Bifidobacterium cultures.
In the first 72 hours of a chick's life, the gut is a "blank slate." Introducing Bifidobacterium animalis via drinking water or early-age feed helps establish a dominant beneficial flora, reducing the incidence of yolk sac infections and improving the Feed Conversion Ratio (FCR).
Weaning is the most stressful period for piglets, often resulting in "post-weaning diarrhea." High-dose Bifidobacterium supplementation supports the intestinal mucosal barrier, preventing the "leaky gut" syndrome that leads to systemic inflammation and stunted growth.
As pet ownership rises globally, the demand for "Human-Grade" probiotics for dogs and cats has skyrocketed. Bifidobacterium is sought after for its ability to reduce flatulence, improve stool quality, and boost the immune system of aging pets.
Currently, the industry is moving away from simple biomass production toward Targeted Metabolomics. We are no longer just selling "bacteria"; we are selling the metabolic by-products they produce, such as Short-Chain Fatty Acids (SCFAs) and B-vitamins. This approach, facilitated by Serum Pharma's investment in advanced bio-fermentation technologies, ensures that our partners receive a product that is biologically active the moment it enters the animal's digestive tract.
Serum Pharma continuously monitors cutting-edge market developments to offer customized solutions.
Tailored probiotic blends designed for specific animal species and growth stages.
Read More →
Advanced molecular techniques to enhance the stability and solubility of active ingredients.
Read More →
State-of-the-art fermentation processes for high-yield, high-purity biological production.
Read More →Exploring the shift toward sustainable sources in the global squalene market and its implications for pharmaceutical grade additives.
Why Dexamethasone Sodium Phosphate remains a critical molecule in modern veterinary and human medicine for inflammatory control.
Analysis of the FDA's rapid approval of Eli Lilly’s Foundayo™ and its impact on the peptide and weight-loss drug industry.
